Omexta Drug Interactions

Drug that block the renin-angiotensin system: Increased risk of renal impairment, hyperkalemia, and hypotension with concomitant use of other drugs that block the renin-angiotensin system (e.g., angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor antagonists, aliskiren); when Olmesartan medoxomil is used concomitantly with such drugs, blood pressure, renal function, and serum concentrations of electrolytes should be monitored closely.
Colesevelam hydrochloride: Colesevelam hydrochloride may decrease systemic exposure and peak plasma concentrations of Olmesartan medoxomil. Administration of Olmesartan medoxomil at least 4 hours prior to colesevelam decreases the extent of this interaction and should be considered.
Lithium: Olmesartan medoxomil may increase serum lithium concentrations resulting in lithium toxicity have been reported. If concomitant use is required, serum lithium concentrations should be carefully monitored.
Nonsteroidal Anti-inflammatory Agents (NSAIDs): When Olmesartan medoxomil is used concomitantly with NSAIDs, including selective COX-2 inhibitors may result in renal dysfunction. Renal function should be monitored periodically in patients receiving concomitant therapy with Olmesartan medoxomil and NSAIDs, including selective COX-2 inhibitors.